Identification and differentiation of hepatocellular carcinoma
Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Arginase-1 is a urea cycle metalloenzyme specifically expressed in hepatocytes. This protein serves as a marker in the identification and differentiation of hepatocellular carcinoma within the context of an antibody panel.
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
This test is not an orderable test. Order 70012 / Pathology Consultation. The consultant will determine the need for special stains.
This test will be processed as a pathology consultation. An interpretation will be provided.
Clinical Reference Provides recommendations for further in-depth reading of a clinical nature
1. Radwan NA, Ahmed NS: The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1. Diagn Pathol 2012;7:149
2. Timek DT, Shi J, Liu H, Lin F: Arginase-1, HepPar-1, and Glypican-3 are the most effective panel of markers in distinguishing hepatocellular carcinoma from metastatic tumor on fine-needle aspiration specimens. Am J Clin Pathol 2012;138(2):203-210
3. Fujiwara M, Kwok S, Yano H, Pai RK: Arginase-1 is a more sensitive marker of hepatic differentiation than HepPar-1 and glypican-3 in fine-needle aspiration biopsies. Cancer Cytopathol 2012;120(4):230-237
4. Yan BC, Gong C, Song J, et al: Arginase-1: a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms. Am J Surg Pathol 2010;34(8):1147-1154